Pinned post
Our latest: Microdose psilocybin improves symptoms of depression, anxiety and demoralization in a palliative setting in phase 2 study. Phase 3 RCT now enrolling!
@bruyerehealth @uOttawaMed @PCPCRCollab @GovCanHealth @cancersociety
journals.sagepub.com/doi/10.1177/02…
@bruyerehealth @uOttawaMed @PCPCRCollab @GovCanHealth @cancersociety
journals.sagepub.com/doi/10.1177/02…